Nirmal Bang target on SEQUENT
Date: 11-May-20
Broker: Nirmal Bang
Price @ Call: 83.13
Target: 97
Recommendation: BUY
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
SEQUENT Share Price Discussion
Sequent Scientific Ltd.
NSE: SEQUENT | BSE: 512529 | ISIN: INE807F01027 | Sector: Pharmaceuticals and health care
SEQUENT Rating
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (1 Ratings)
SEQUENT Share Price *
84.35 +1.25 (1.5%)
* (quote may be delayed)
Find answers to all your questions on live SEQUENT message board: Is SEQUENT buy or sell? Should I buy SEQUENT shares? Why are SEQUENT shares falling? Should I invest in SEQUENT stock?
You can also check SEQUENT share price target recommended by brokerages.
SEQUENT Discussion Forum > Posts
Reputation: 2,889 • May 8 1:38 AM
Carlyle Group acquires majority stake in animal health company Sequent Scientific
Carlyle Group will acquire a majority stake via private share purchase agreement, at Rs 86 per share
Carlyle Group will acquire a majority stake via private share purchase agreement, at Rs 86 per share
Moneycontrol
Like
Reply
Reputation: -1,681 • Apr 29 6:43 AM
SEQUENT SCIENTIFIC: PROMOTER RELEASES PLEDGE ON 1.4M SHARES FROM APRIL 27-28
Like
Reply
Reputation: -1,681 • Apr 9 7:40 AM
*SEQUENT SCIENTIFIC Rs 44.37 CRS NSE BLOCK FOR ~ 5688011 SHARES, AT RS 78*
Like
Reply
Reputation: -1,681 • Jan 14 6:48 AM
FORWARD...
Sequent Scientific will be acquired by Advent International. Announcement Possible tomorrow.
Like
Reply
Reputation: 2,889 • Sep 30 7:53 AM
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
Reply
Reputation: 1,590 • Aug 29 8:11 AM
HALAL INVESTMENT in SEQUENTSEQUENT ACHV 2ND TARGET..HOLD 4 NEXT...❣
1
Reply
Reputation: 1,590 • Aug 27 8:27 AM
HALAL INVESTMENT in SEQUENTSEQUENT...71.45 BUY RANGE 70 TO 68 PUT 66 AS CB...
SEQUENT ACHV 2ND TARGET..HOLD 4 NEXT...❣
Like
Reply
Reputation: 1,590 • Aug 27 6:10 AM
HALAL INVESTMENTSEQUENT...71.45 BUY RANGE 70 TO 68 PUT 66 AS CB...
SEQUENT ACHV 1ST TARGET...❣ HOLD ON
1
Reply
Reputation: 2,889 • Aug 21 3:28 AM
Sequent Scientific climbs 4% on EIR from USFDA for Bengaluru laboratory
The Bengaluru laboratory was set up in 2017 to cater to the growing analytical requirements of large pharmaceutical and FMCG majors in the region.
The Bengaluru laboratory was set up in 2017 to cater to the growing analytical requirements of large pharmaceutical and FMCG majors in the region.
Moneycontrol
Like
Reply
Reputation: 2,889 • Apr 16 10:18 AM
Buy Sequent Scientific; target of Rs 116: Joindre Capital Services
Like
Reply
Reputation: 2,889 • Dec 19 7:57 AM
Ten BSE 500 stocks rise 45-100% since October. Do you own any?
Like
Reply
Reputation: 2,889 • Dec 13 7:02 AM
Sequent Scientific gains 4% on EIR from USFDA for Mangalore lab
Like
Reply
Reputation: 2,889 • Nov 5 4:12 AM
Buy Sequent Scientific, target Rs 61: Rudra Shares & Stock Brokers
Like
Reply
Reputation: 2,889 • Nov 5 2:12 AM
Time to buy quality: Can start accumulating corporate banks, pharma stocks
Like
Reply
- NewsBotMay 8 1:38 AMCarlyle Group acquires majority stake in animal health company Sequent ScientificMoneycontrolNewsBotSep 30 7:53 AMRanitidine controversy: Which Indian pharma companies stand to lose?MoneycontrolNewsBotAug 21 3:28 AMSequent Scientific climbs 4% on EIR from USFDA for Bengaluru laboratoryMoneycontrolNewsBotApr 16 10:18 AMBuy Sequent Scientific; target of Rs 116: Joindre Capital ServicesNewsBotDec 19 7:57 AMTen BSE 500 stocks rise 45-100% since October. Do you own any?NewsBotDec 19 7:37 AMTen BSE 500 stocks rose 45-100% in 2018. Do you own any?NewsBotDec 13 7:02 AMSequent Scientific gains 4% on EIR from USFDA for Mangalore labNewsBotNov 5 4:12 AMBuy Sequent Scientific, target Rs 61: Rudra Shares & Stock BrokersNewsBotNov 5 2:12 AMTime to buy quality: Can start accumulating corporate banks, pharma stocks
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.